Akeso: Neoplasms trials

The registry lists 19 Neoplasms studies with Akeso as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 17Phase 2 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant TumorsNot yet recruitingNCT06691360Phase 1
• A Study of AK131 in Patients With Advanced Solid TumorsRecruitingNCT06166888Phase 1
• A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid TumorNot yet recruitingNCT06166472Phase 1
• A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant TumorsRecruitingNCT05868876Phase 1
• A Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsRecruitingNCT05142423Phase 1/2
• A Study of AK130 in Patients With Advanced Malignant TumorsCompletedNCT05653284Phase 1
• Study of AK119 Combined With AK104 in Patients With Advanced Solid TumorsTerminatedNCT05559541Phase 1/2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114Status unknownNCT05200273Phase 1
• Study of AK119 in Subjects With Advanced Solid TumorsCompletedNCT05173792Phase 1
• Study of AK112 in the Treatment of Advanced Gynecological TumorsCompletedNCT04870177Phase 2
• A Phase 1 Dose Escalation and Expansion Study of AK117CompletedNCT04728334Phase 1
• A Study of AK112 for Advanced Solid TumorsCompletedNCT04597541Phase 1/2
• A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid TumorsCompletedNCT04572152Phase 1
• A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid TumorsCompletedNCT04547205Phase 1
• A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid TumorsTerminatedNCT04547101Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedNCT04349969Phase 1
• A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid TumorsCompletedNCT04172506Phase 1/2
• Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsCompletedNCT04172454Phase 1/2
• A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsCompletedNCT04047290Phase 1